Download PDF
Aktuelle Neurologie 2011; 38(04): 190-202
DOI: 10.1055/s-0031-1279769
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Was gibt es Neues bei der Multiplen Sklerose?

Multiple Sclerosis Update
M. Marziniak
1   Universitätsklinikum Münster, Klinik für Neurologie – Entzündliche Erkrankungen des Nervensystems und Neuroonkologie, Münster
,
S.G. Meuth
1   Universitätsklinikum Münster, Klinik für Neurologie – Entzündliche Erkrankungen des Nervensystems und Neuroonkologie, Münster
,
R. Gold
2   Neurologische Universitätsklinik St. Josef Hospital, Klinikum der Ruhr-Universität Bochum, Bochum
,
H. Wiendl
1   Universitätsklinikum Münster, Klinik für Neurologie – Entzündliche Erkrankungen des Nervensystems und Neuroonkologie, Münster
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Dieser Übersichtsartikel informiert über Studienergebnisse der letzten 12 Monate zum Thema Multiple Sklerose (MS) sowie die neuesten Ergebnisse vom 26. Kongress des Europäischen Komittees zur Behandlung und Forschung der Multiplen Sklerose (ECTRIMS). Schwerpunkt sind die klinisch relevanten Studien und die Darstellung der Datenlage zu den zukünftigen oralen und Antikörper basierten Therapieoptionen der Multiplen Sklerose. Obwohl die Therapiemöglichkeiten für MS in den vergangenen Jahrzehnten deutlich erweitert wurden, werden neue Behandlungsoptionen und komfortablere Formen der Anwendung benötigt, um die Effizienz der Therapie zu erhöhen und die Therapieadhärenz zu verbessern. Die Zulassung der ersten oralen Substanz in der Behandlung der schubförmigen MS, Fingolimod, erfolgte im März 2011. Die aktuell nicht erteilte Zulassung für Cladribin zur Behandlung der schubförmigen Form der Multiplen Sklerose zeigt jedoch auch den schmalen Grat zwischen Therapienutzen und möglichen noch nicht beurteilbaren Nebenwirkungen der neuen Therapieoptionen. Dieser Artikel wird die jüngsten Entwicklungen auf dem Gebiet der MS-Behandlung referieren und dabei den Schwerpunkt auf die oralen Wirkstoffe (Fingolimod, Cladribin, BG00012, Teriflunomid und Laquinimod) sowie 2 neue monoklonale Antikörper (Alemtumzumab und Daclizumab) legen. Eine weitere relevante Neuerung 2011 ist ein Revisionsvorschlag zum MRT in der Diagnosestellung der MS aus der MAGNIMS Gruppe. Dieser Vorschlag erlaubt die Diagnose einer gesicherten MS nach erstem klinischem Ereignis, nun noch frühzeitiger zu stellen. Erste Ergebnisse zu Risikoprädiktionsalgorithmen sowie Biomarkern für das Risiko einer Immuntherapie mit Natalizumab liegen vor, mit dem Nachweis des anti-JCV-Antikörper im Serum scheint es einen ersten Biomarker zur Abschätzung des PML-Risikos einer progressiven multifokalen Leukenzephalopathie (PML) unter einer Natalizumabtherapie zu geben. Unter Berücksichtigung einer immunsuppressiven Vortherapie kann sich das individuelle PML Risiko bei gegebener Konstellation (immunsuppressive Vortherapie und Vorliegen von JC-Antikörpern) teilweise um den Faktor 10 und mehr unterscheiden. Neue Erkenntnisse zur Pathogenese, Genetik, Rolle von Umweltfaktoren, Diagnosestellung und Prognose werden zusammengestellt.

Abstract

This review reports on the results of clinical trials in multiple sclerosis of the last 12 months. The review focuses on the new oral immunotherapies and monoclonal antibodies as therapeutic options in the treatment of multiple sclerosis. Although the drug therapy has improved in multiple sclerosis during the last years, new therapeutic options are necessary to improve the efficacy and the adherence of patients to drugs. The first oral drug, fingolimod, in remitting-relapsing multiple sclerosis was approved in March 2011 in Europe after approval by the FDA in 2010. The postponed approval for cladribine by the EMA illustrates the difficult benefit-risk estimation of new drugs in multiple sclerosis. The new developments of new orals (cladribine, fingolimod, BG00012, teriflunomide and laquinimod) and two monoclonal antibodies alemtuzumab and daclizumab are described. The MAGNIMS criteria to diagnose MS with a cranial MRI scan enable the clinicians to determine the confirmed diagnosis of MS earlier after the clinically isolated syndrome. The anti-JC-virus antibody seems to be the first reliable biomarker to estimate the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients. Under consideration of a former immunosuppressive therapy, the individual risk for PML differs by about a factorof 10 or more under natalizumab therapy.

Schlüsselwörter:

Multiple Sklerose - Cladribin - Fingolimod - Laquinimod - Teriflunomid

Key words:

multiple sclerosis - cladribine - fingolimod - laquinimod - teriflunomide
 

  • Literatur

  • 1 Hoffjan S, Akkad DA. The genetics of multiple sclerosis: an update 2010. Mol Cell Probes 2010; 24: 237-243
    CrossrefPubMedGoogle Scholar
  • 2 Byun E, Caillier SJ, Montalban X et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344
    CrossrefPubMedGoogle Scholar
  • 3 Simpson Jr S, Taylor B, Blizzard L et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193-203
    PubMedGoogle Scholar
  • 4 Munger KL, Levin LI, Hollis BW et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-2838
    CrossrefPubMedGoogle Scholar
  • 5 Correale J, Ysrraelit MC, Gaitan MI. Immunmodulatory effects of vitamin D in multiple sclerosis. Brain 2009; 132: 1146-1160
    CrossrefPubMedGoogle Scholar
  • 6 Hedström AK, Bäärnhielm M, Olsson T. Tobacco smoking but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009; 73: 696-701
    CrossrefPubMedGoogle Scholar
  • 7 Handel AE, Williamson AJ, Dissanto G et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLos One 2010; 5 (09) Pii: e12496
    CrossrefPubMedGoogle Scholar
  • 8 Montalban X, Tintore M, Swanton J et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74: 427-434
    CrossrefPubMedGoogle Scholar
  • 9 Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-2069
    CrossrefPubMedGoogle Scholar
  • 10 Swanton JK, Fernando K, Dalton CM et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77: 830-833
    CrossrefPubMedGoogle Scholar
  • 11 Swanton JK, Rovira A, Tintore M et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007; 6: 667-686
    CrossrefPubMedGoogle Scholar
  • 12 Polman CH, Reingold SC, Banwell B et al. Diagnostic Criteria for multiple sclerosis: 2010 Revisions to the „Mc Donald Criteria“. Ann Neurol 2011; 69: 292-302
    CrossrefPubMedGoogle Scholar
  • 13 Lebrun C, Bensa C, Debouverie M et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome. Arch Neurol 2009; 66: 841-846
    CrossrefPubMedGoogle Scholar
  • 14 Sellner J, Schirmer L, Hemmer B et al. The radiologically isolated syndrome: take action when the unexpected is suncovered?. J Neurol 2010; 257: 1602-1611
    CrossrefPubMedGoogle Scholar
  • 15 Tintore M, Rovira A, Rio J et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008; 70: 1079-1083
    PubMedGoogle Scholar
  • 16 Bosca I, Magraner MJ, Coret F et al. The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. J Neuroimmunol 2010; 226: 143-146
    CrossrefPubMedGoogle Scholar
  • 17 Barachini C, Perini P, Calabrese M et al. No evidence of chronic cerebrospinal venous insufficiency in clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis 2010; 16: S24
    PubMedGoogle Scholar
  • 18 Doepp F, Paul F, Valdueza JM et al. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol 2010; 68: 173-183
    PubMedGoogle Scholar
  • 19 Zivadinov R, Poloni G, Schirda C et al. Presence and severity of chronic cerebrospinal venous insufficiency is related to lower brain parenchyma venous vasculature on susceptibility-weighted imaging in patients with multiple sclerosis. Multiple Sclerosis 2010; 16: 24
    PubMedGoogle Scholar
  • 20 Zamboni P, Galeotti R, Menegatti E et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 392-399
    PubMedGoogle Scholar
  • 21 Krogias C, Schröder A, Wiendl H et al. „Chronic cerebrospinal venous insufficiency“ and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients. Nervenarzt 2010; 81: 740-746
    CrossrefPubMedGoogle Scholar
  • 22 Rudick RA, O’Connor PW, Polman CH et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010; 68: 304-310
    CrossrefPubMedGoogle Scholar
  • 23 Gorelik L, Lerner M, Bixler S et al. Anti-JCV antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303
    CrossrefPubMedGoogle Scholar
  • 24 Warnke C, Adams O, Gold R et al. Progressive multifocal leukoencephalopathy under natalizumab : Initial possibilities for risk stratification?. Nervenarzt 2011; 82: 475-480 Jan 16 [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 25 Bozic C, Cristiano LM, Hyde R et al. Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis. Multiple Sclerosis 2010; 16: 315
    PubMedGoogle Scholar
  • 26 Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (novantrone) in the treatment of multiple sclerosis. Neurology 2010; 74: 1463-1470
    CrossrefPubMedGoogle Scholar
  • 27 Martinelli V, Bergmaschi R, Bellantonio P et al. Incidence rate of acute myeloid leukaemia and related mortality in Italian MS patients treated with mitoxantrone. Multiple Sclerosis 2010; 16: 160-161
    PubMedGoogle Scholar
  • 28 Hiestand PC, Rausch M, Meier DP et al. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720. Prog Drug Res 2008; 66 (361) 363-381
    PubMedGoogle Scholar
  • 29 Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29: 558-565
    CrossrefPubMedGoogle Scholar
  • 30 Coelho RP, Payne SG, Bittman R et al. The immunomodulator FTY720 has a direct cytoprotective effekt in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007; 323: 626-635
    CrossrefPubMedGoogle Scholar
  • 31 Miron VE, Jung CG, Kim HJ et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63: 61-71
    CrossrefPubMedGoogle Scholar
  • 32 Mullershausen F, Craveiro LM, Shin Y et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007; 102: 1151-1161
    CrossrefPubMedGoogle Scholar
  • 33 Balatoni B, Storch MK, Swoboda EM et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007; 74: 307-316
    CrossrefPubMedGoogle Scholar
  • 34 Fujino M, Funeshima N, Kitazawa Y et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70-77
    CrossrefPubMedGoogle Scholar
  • 35 Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415
    CrossrefPubMedGoogle Scholar
  • 36 Lim SY, Constantinescu CS. Current and future disease-modifying therapies in multiple sclerosis. Int J Clin Pract 2010; 64: 637-650
    CrossrefPubMedGoogle Scholar
  • 37 Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401
    CrossrefPubMedGoogle Scholar
  • 38 www.fda.gov/…Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM 227965.pdf -
    PubMed
  • 39 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/smops/Positive/human_smop_000174.jsp&mid=WC0b01ac058001d127&murl=menus/medicines/medicines.jsp&jsenabled=true
    PubMed
  • 40 Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-956
    CrossrefPubMedGoogle Scholar
  • 41 Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005; 5: 721-727
    CrossrefPubMedGoogle Scholar
  • 42 Beutler E, Sipe JC, Romine JS et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996; 93: 1716-1720
    CrossrefPubMedGoogle Scholar
  • 43 Sipe JC, Romine JS, Koziol JA et al. Development of cladribine treatment in multiple sclerosis. Mult Scler 1996; 1: 343-347
    PubMedGoogle Scholar
  • 44 Romine JS, Sipe JC, Koziol JA et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35-44
    CrossrefPubMedGoogle Scholar
  • 45 Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426
    CrossrefPubMedGoogle Scholar
  • 46 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001197/smops/Negative/human_smop_000139.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d127
    PubMed
  • 47 www.fda.gov/…/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166167.pdf
    PubMed
  • 48 Lee DH, Linker RA, Gold R. Spotlight on fumarates. Int MS J 2008; 15: 12-18
    PubMedGoogle Scholar
  • 49 Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-1472
    CrossrefPubMedGoogle Scholar
  • 50 Brunmark C, Runstrom A, Ohlsson L et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130: 163-172
    CrossrefPubMedGoogle Scholar
  • 51 Jonsson S, Andersson G, Fex T et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004; 47: 2075-2088
    CrossrefPubMedGoogle Scholar
  • 52 Runstrom A, Leanderson T, Ohlsson L et al. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173: 69-78
    CrossrefPubMedGoogle Scholar
  • 53 Yang JS, Xu LY, Xiao BG et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156: 3-9
    CrossrefPubMedGoogle Scholar
  • 54 Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 2009; 18: 985-989
    CrossrefPubMedGoogle Scholar
  • 55 Polman C, Barkhof F, Sandberg-Wollheim M et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987-991
    CrossrefPubMedGoogle Scholar
  • 56 Comi G, Pulizzi A, Rovaris M et al. Effekt of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-2092
    CrossrefPubMedGoogle Scholar
  • 57 Korn T, Magnus T, Toyka K et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004; 76: 950-960
    CrossrefPubMedGoogle Scholar
  • 58 Kaplan MJ. Leflunomide Aventis Pharma. Curr Opin Investig Drugs 2001; 2: 222-230
    PubMedGoogle Scholar
  • 59 Korn T, Toyka K, Hartung HP et al. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001; 124: 1791-1802
    CrossrefPubMedGoogle Scholar
  • 60 Smolen JS, Emery P, Kalden JR et al. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol Suppl 2004; 71: 13-20
    PubMedGoogle Scholar
  • 61 O’Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900
    CrossrefPubMedGoogle Scholar
  • 62 O’Connor P, Wolinsky J, Confaveux C et al. A placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes. Multiple Sclerosis 2010; 16: S23
    PubMedGoogle Scholar
  • 63 Hale G, Bright S, Chumbley G et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873-882
    PubMedGoogle Scholar
  • 64 Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005; 10: 79-93
    PubMedGoogle Scholar
  • 65 Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108
    CrossrefPubMedGoogle Scholar
  • 66 Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-1695
    CrossrefPubMedGoogle Scholar
  • 67 Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304
    CrossrefPubMedGoogle Scholar
  • 68 Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-2061
    PubMedGoogle Scholar
  • 69 Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801
    Google Scholar
  • 70 Fox E, Mayer L, Sullivan H et al. Two-year results with alemtuzumab in patients with active relapsing-remitting multiple sclerosis who have failed licensed beta interferon therapies. Multiple Sclerosis 2007; 13 (Suppl. 02) S166-167
    PubMedGoogle Scholar
  • 71 Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 2008; 8: 433-455
    CrossrefPubMedGoogle Scholar
  • 72 Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 2010; 10: 791-809
    CrossrefPubMedGoogle Scholar
  • 73 Waldmann TA, O’Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10: 507-512
    CrossrefPubMedGoogle Scholar
  • 74 Nussenblatt RB, Fortin E, Schiffman R et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999; 96: 7462-7466
    CrossrefPubMedGoogle Scholar
  • 75 Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5941-5946
    CrossrefPubMedGoogle Scholar
  • 76 Bielekova B, Richert N, Howard T et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004; 101: 8705-8708
    CrossrefPubMedGoogle Scholar
  • 77 Rose JW, Watt HE, White AT et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56: 864-867
    CrossrefPubMedGoogle Scholar
  • 78 Rose JW, Burns JB, Bjorklund J et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69: 785-789
    CrossrefPubMedGoogle Scholar
  • 79 Wynn D, Kaufman M, Montalban X et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9: 381-390
    CrossrefPubMedGoogle Scholar
  • 80 Lutterotti A, Berger T. Advances in Multiple Sclerosis Therapy: New Oral Disease Modifying Agents. CML – Multiple Sclerosis 2010; 2: 1-10
    PubMedGoogle Scholar
  • 81 Phase III. Clinical trial using daclizumab for relapsing-remitting multiple sclerosis inititated. Immunotherapy 2010; 2: 437
    CrossrefPubMedGoogle Scholar
  • 82 Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 2010; 3: 93-105
    CrossrefPubMedGoogle Scholar
  • 83 Hawker K, O’Connor PW, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis. Ann Neurol 2009; 66: 460-471
    CrossrefPubMedGoogle Scholar
  • 84 Kappos L, Calabresi P, O’Connor P et al. Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis 2010; 16: S33
    PubMedGoogle Scholar
  • 85 Soelberg Sorensen P, Drulovic J, Havrdova E et al. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) – 24-week results of a phase II study. Multiple Sclerosis 2010; 16: S37
    PubMedGoogle Scholar